Originally approved for children with spinal muscular atrophy aged 2 months and older, risdiplam is now indicated for presymptomatic children younger than 2 months.
FDA Approvals
FDA Approvals
FDA Expands Indication for Spinal Muscular Atrophy Drug
Originally approved for children with spinal muscular atrophy aged 2 months and older, risdiplam is now indicated for presymptomatic children younger than 2 months.
FDA Approvals
FDA Approvals